Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07123727 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Examine Anktiva for the Treatment of COVID-19.

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Jul 2026 → Mar 2027
See other at-risk trials from ImmunityBio, Inc.

Record History

  1. Primary and study completion pushed from Jul 2026 to Mar 2027 Eligibility criteria expanded, about 28 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 28 words
  2. Re-verified, no change to tracked fieldsv4
  3. Start date changed from estimate of Sep 2025 to Sep 4, 2025v3
  4. Start date: Aug 2025 to Sep 2025 Site contact updatedv2 Show 1 more changeShow less
    • Site contact updated
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
Trial Details
NCT Number NCT07123727
Lead Sponsor ImmunityBio, Inc.
Conditions Long COVID, Long COVID Syndrome, Long Covid 19
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov